Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
Featured Image

$21.4M in State Tax Breaks for 19 Biotechs

  • Posted by ISPE Boston
  • On October 18, 2024
The Healey-Driscoll administration and the Massachusetts Life Sciences Center (MLSC) have announced $21.4 million in tax incentive awards to 19 life sciences companies. The awards, provided through the MLSC’s Tax Incentive Program, are expected to create 1,155 new life sciences industry jobs in Massachusetts. The MLSC Tax Incentive program is offered to companies engaged in life […]
Read More
 
 Featured Image

FDA Approves First-in-Class Schizophrenia Drug from BMS

  • Posted by ISPE Boston
  • On October 18, 2024
The FDA has approved Cobenify, an oral medication for the treatment of schizophrenia in adults. Cobenify represents the first new class of schizophrenia medicine in several decades and introduces a fundamentally new approach to treating the illness. “Today’s landmark approval of our first-in-class treatment for schizophrenia marks an important milestone for the community, where after more […]
Read More
 
 Featured Image

Introducing New Board Member Sean Keenan

  • Posted by ISPE Boston
  • On October 14, 2024
A big welcome to Sean Keenan, the newest member of the Chapter’s Board of Directors! Although new to the Board, Sean has long been an active Chapter volunteer, including Chair of the Emerging Leaders Committee (ELC). In order to get to know him better, we asked Sean a few questions about his background as a […]
Read More
 
 Featured Image

Webinar Invitation – Recent Advances in Cell and Gene Therapy

  • Posted by Sunny Tam
  • On October 10, 2024
You’re invited! Longtime ISPE Boston Area Chapter board member, Professor Sunny Tam, is organizing an international online panel on Recent Advances in Cell & Gene Therapy as a collaboration between Northeastern University and The Hong Kong University of Science and Technology. Panelists include: Professor Lo Yuk Lam, President, Hong Kong Bio-Med Innotech Association Dr. Simon […]
Read More
 
 Featured Image

A Rainy but Fun Fall Golf Tournament

  • Posted by Dan Kenny
  • On October 9, 2024
On a rainy Monday, ISPE members and non-members gathered at Indian Pond Golf Club for the annual Fall Golf Tournament to benefit the ISPE Boston Scholarship Foundation. Despite a brief rain delay, foursomes set out in good spirits for a day out on the golf course. As the day wore on, and the rain continued, […]
Read More
 
 Featured Image

Chapter Member Anniversaries: October 2024

  • Posted by ISPE Boston
  • On October 9, 2024
Please congratulate the following members celebrating milestone anniversaries in October 2024.  Their dedication to ISPE, the Boston Area Chapter and the industry is applauded! Over Twenty Years Louis R. Cicchese, MBA, BSChem, Moderna Therapeutics Aaron Conant, Alnylam Pharmaceuticals Patrick J. Cunneen, Allegheny Bradford Corp. William G. Devine, Pharma-Tech Services Ric Feldt, Jeff Smith & Associates […]
Read More
 
 Featured Image

Welcome New Members September 2024

  • Posted by ISPE Boston
  • On October 9, 2024
We would like to introduce the Members who joined ISPE in September 2024, welcome them to the Chapter, and encourage them (and all our members) to take advantage of the many professional development, networking and information resources available through ISPE. Fellow ISPE members are a terrific resource for help with everyday professional challenges. And the […]
Read More
 
 Featured Image

Another New Chapter Board Member Joins the Team: Stephen Kerr

  • Posted by ISPE Boston
  • On September 23, 2024
The results are in and the new ISPE Boston Board Members have been chosen! We asked all of them some interview questions so that you could get to know them better!  1. What do you currently do? I’m currently a Professor of Medicinal Chemistry and the Associate Provost for Academic and International Affairs at the […]
Read More
 
 Featured Image

Local Biotechs Go Public, Raise Over $500M Total

  • Posted by ISPE Boston
  • On September 19, 2024
Boston-based Bicara Therapeutics, a clinical-stage biopharma developing therapies for patients with solid tumors, this week announced the closing of its initial public offering which raised gross proceeds of approximately $362 million. Bicara’s lead asset, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody […]
Read More